首页> 外文期刊>Journal of Medicinal Chemistry >Carbonic anhydrase and matrix metalloproteinase inhibitors: Sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes [Revie
【24h】

Carbonic anhydrase and matrix metalloproteinase inhibitors: Sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes [Revie

机译:碳酸酐酶和基质金属蛋白酶抑制剂:具有MMP抑制特性的磺酰氨基酸异羟肟酸酯可作为CA同工酶I,II和IV的有效抑制剂,而N-羟基磺酰胺可抑制这两种锌酶[Revie

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The 14 different carbonic anhydrase (CA, EC 4.2.1.1) isozymes as well as the 23 different matrix metalloproteinases (MMPs) isolated up to now in higher vertebrates play important physiological functions in these organisms. Unsubstituted sulfonamides act as high-affinity inhibitors for the first type of these enzymes, whereas hydroxamates strongly inhibit the latter ones. Since the active Bite geometry around the zinc ion in these two types of metalloenzymes is rather similar, we tested whether sulfonylated amino acid hydroxamates of the type RSO2-NX-AA-CONHOH(X = H, benzyl, substituted benzyl; AA = amino acid moiety, such as Gly, Ala, Val, Leu) with well-known inhibitory properties against MMPs and Clostridium histolyticum collagenase (ChC, another zinc enzyme related to the MMPs) might also act as CA inhibitors. We also investigated whether N-hydroxysulfonamides of the type RSO2NHOH (which are effective CA inhibitors) inhibit MMPs and ChC. Here we report several. potent sulfonylated amino acid hydroxamate CA inhibitors (with inhibition constants in the range of 5-40 nM, against, the human isozymes hCA I and hCA II, and 10-50 nM, against the bovine isozyme bCA IV), as well as preliminary SAR for this new class of non-sulfonamide CA inhibitors. Some N-hydroxysulfonamides also showed inhibitory properties (in the micromolar range) against MMP-1, MMP-2, MMP-8, MMP-9, and ChC. Thus, the SO2NHOH group is a new zinc-binding function for the design of MMP inhibitors. Both CA as well as MMPs are involved, among others, in carcinogenesis and tumor invasion processes. On the basis of these findings, we suggest that the mechanism of antitumor action with some hydroxamate inhibitors might also involve inhibition of some CA isozymes (such as CA IX, CA XII, and CA XIV) present only in tumor cell membranes, in addition to collagenases/gelatinases of the MMP type. Our data also suggest that it should be possible to develop dual enzyme inhibitors that would strongly inhibit both these metalloenzymes, CAs and MMPs, based on the nature of the R, AA, and X moieties in the above formula. Compact X (such as H) and AA (such as Gly) moieties favor CA over MMP inhibition, whereas bulkier X (benzyl, substituted benzyl, etc.) and AA (such as Val, Leu) moieties and substituted-aryl R groups are advantageous for obtaining potent MMP and ChC inhibitors, which show lower affinity for CA. [References: 101]
机译:迄今为止,在高等脊椎动物中分离出的14种不同的碳酸酐酶(CA,EC 4.2.1.1)同工酶以及23种不同的基质金属蛋白酶(MMP)在这些生物中起着重要的生理功能。未取代的磺酰胺类对这些酶的第一类起高亲和力抑制剂的作用,而异羟肟酸酯则强烈抑制后一种。由于在这两种类型的金属酶中锌离子周围的活性Bite几何形状相当相似,因此我们测试了RSO2-NX-AA-CONHOH类型的磺酰化氨基酸异羟肟酸酯(X = H,苄基,取代的苄基; AA =氨基酸)对MMP和溶组织梭状芽孢杆菌胶原酶(ChC,与MMP相关的另一种锌酶)具有众所周知的抑制特性的Gly,Ala,Val,Leu等部分也可能用作CA抑制剂。我们还研究了RSO2NHOH类型的N-羟基磺酰胺(有效的CA抑制剂)是否抑制MMP和ChC。在这里我们报告几个。强大的磺酰化氨基酸异羟肟酸酯CA抑制剂(对人同工酶hCA I和hCA II的抑制常数为5-40 nM,对牛同工酶bCA IV的抑制常数为10-50 nM)以及初步SAR这类新型非磺酰胺CA抑制剂。一些N-羟基磺酰胺类药物还表现出对MMP-1,MMP-2,MMP-8,MMP-9和ChC的抑制特性(在微摩尔范围内)。因此,对于MMP抑制剂的设计,SO 2 NHOH基团是新的锌结合功能。 CA以及MMP都参与致癌和肿瘤侵袭过程。基于这些发现,我们建议使用某些异羟肟酸酯抑制剂的抗肿瘤作用机制可能还涉及抑制仅存在于肿瘤细胞膜中的某些CA同工酶(例如CA IX,CA XII和CA XIV)。 MMP类型的胶原酶/明胶酶。我们的数据还表明,根据上式中R,AA和X部分的性质,应该有可能开发出能够强烈抑制这些金属酶,CA和MMP的双重酶抑制剂。紧密X(例如H)和AA(例如Gly)部分比MMP抑制更倾向于CA,而较大的X(苄基,取代的苄基等)和AA(例如Val,Leu)部分和取代的芳基R基团有利于获得有效的MMP和ChC抑制剂,这些抑制剂对CA的亲和力较低。 [参考:101]

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号